ArticleMediators of inflammation2020
TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients.
Article in Mediators of inflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 25 citations in OpenAlex.
- TREM2 in glioma: Reprogramming the immune microenvironment from mechanistic understanding to clinical translation (Review).Molecular medicine reports · 2026Review
- TREM2 inhibits cholangiocarcinoma progression by regulating the TGF-β/Smad2/3 signaling pathway.American journal of cancer research · 2026Article
- Mendelian randomization and single-cell analysis reveal novel genetic risk factors and cellular heterogeneity in glioblastoma.Discover oncology · 2025Article
- The Association Between Serum HMGB2 Levels and Abdominal Aortic Aneurysm in Males: Insights Into the HMGB2-TREM Pathway.Reviews in cardiovascular medicine · 2025Article
- Mental distress and inflammation in bladder cancer: The nerve makes things less vague.Brain, behavior, & immunity - health · 2025Article
- Pilot Screening of TREM1 Inhibitors in Cell-Based Reporter Assays Reflecting TREM1/DAP12 Receptor Assembly and Functionality.ACS chemical neuroscience · 2025Article
- Association of Sympathovagal Imbalance with Increased Inflammation and Impaired Adaptive Immunity in Bladder Cancer Patients.International journal of molecular sciences · 2024Article
- Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression.Frontiers in oncology · 2024Review
- TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma.Science advances · 2023Article
- TREM2 as an independent predictor of poor prognosis promotes the migration via the PI3K/AKT axis in prostate cancer.American journal of translational research · 2023Article
- The role of triggering receptor expressed on myeloid cells-1 (TREM-1) in central nervous system diseases.Molecular brain · 2022Review
- The emerging role of triggering receptor expressed on myeloid cell-2 in malignant tumor.Central-European journal of immunology · 2022Review
- Triggering Receptors Expressed on Myeloid Cells 1 : Our New Partner in Human Oncology?Frontiers in oncology · 2022Review
- The ratio of urinary TREM-1/TREM-2 mRNA expression in chronic kidney disease and renal fibrosis.Annals of medicine · 2021Article
- Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates.Expert opinion on therapeutic patents · 2021Review
- Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC.International journal of molecular sciences · 2021Article
- STATegra: Multi-Omics Data Integration - A Conceptual Scheme With a Bioinformatics Pipeline.Frontiers in genetics · 2021Article
- Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.Frontiers in immunology · 2021Article
- Temozolomide Treatment Induces HMGB1 to Promote the Formation of Glioma Stem Cells via the TLR2/NEAT1/Wnt Pathway in Glioblastoma.Frontiers in cell and developmental biology · 2021Article
- Targeting the TREM1-positive myeloid microenvironment in glioblastoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn recent years, the role of the modern inflammatory markers TREM-1 (triggering receptors expressed on myeloid cells) and HMGB1 (high mobility group box 1 protein) in tumorigenesis has begun to be studied. Their role in gliomas is not clear. The aim of our study was to find the role of inflammation in gliomas.
resultsCox proportional hazard analysis showed that a TREM-1/TREM-2 ratio was associated with reduced overall survival (HR = 1.001,
conclusionWe showed that the TREM-1/TREM-2 ratio (expression on the surface of blood monocytes) could help predict prognosis in patients with gliomas, especially in high-grade gliomas, and that systemic inflammation has an impact on the patient's overall survival. This is the first study that showed that TREM expression on monocytes in peripheral blood could help predict prognosis in patients with gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.